Rapamycin extends murine lifespan but has limited effects on aging

• DOI: 10.1172/jci67674
• Publication Date: 2013-07-24T18:27:28Z
• Authors: Frauke Neff; Diana Flores-Domi...; Devon P. Ryan; Marion Horsch; Susanne Schröder; Thure Adler; Luciana Caminha A...; Juan Antonio Agui...; Lore Becker; Lillian Garrett; Wolfgang Hans; Moritz M. Hettich; Richard Holtmeier; Sabine M. Hölter; Kristin Moreth; Cornelia Prehn; Oliver Puk; Ildikó Rácz; Birgit Rathkolb; Jan Rozman; Beatrix Naton; Rainer Ordemann; Jerzy Adamski; Johannes Beckers; Raffi Bekeredjian; Dirk H. Busch; Gerhard Ehninger; Jochen Graw; Heinz Höfler; Martin Klingenspor; Thomas Klopstock; Markus Ollert; Jörg Stypmann; Eckhard Wolf; Wolfgang Wurst; Andreas Zimmer; Helmut Fuchs; Valérie Gailus-Du...; Martin Hrabe de A...; Dan Ehninger
• Keywords: Liver Cirrhosis; Male; Aging; Longevity; pharmacology [Sirolimus]; Drug Evaluation, Preclinical; Immunoglobulins; mTOR protein, mouse; drug effects [Longevity]; drug effects [Maze Learning]; immunology [T-Lymphocytes]; Leukocyte Count; Mice; Oxygen Consumption; drug effects [Oxygen Consumption]; Animals; ddc:610; Muscle Strength; Maze Learning; Sirolimus; drug effects [T-Lymphocytes]; Granuloma; Platelet Count; drug effects [Muscle Strength]; TOR Serine-Threonine Kinases; pathology [Thyroid Gland]; Survival Analysis; drug effects [Aging]; pathology [Liver]; 3. Good health; Mice, Inbred C57BL; blood [Immunoglobulins]; prevention & control [Granuloma]; drug effects [Liver]; Cell Transformation, Neoplastic; Phenotype; Liver; drug effects [Cell Transformation, Neoplastic]; drug effects [Thyroid Gland]; antagonists & inhibitors [TOR Serine-Threonine Kinases]; prevention & control [Liver Cirrhosis]; drug effects [Psychomotor Performance]; Psychomotor Performance

Aging is a major risk factor for large number of disorders and functional impairments. Therapeutic targeting the aging process may therefore represent an innovative strategy in quest novel broadly effective treatments against age-related diseases. The recent report lifespan extension mice treated with FDA-approved mTOR inhibitor rapamycin represented first demonstration pharmacological maximal mammals. Longevity effects may, however, be due to rapamycin’s on specific life-limiting pathologies, such as cancers, it remains unclear if this compound actually slows rate Here, we present results from comprehensive, large-scale assessment wide range structural phenotypes, which performed determine whether male C57BL/6J mice. While did extend lifespan, ameliorated few studied phenotypes. A subset traits appeared rescued by rapamycin. Rapamycin, had similar many these young animals, indicating that were not modulation aging, but rather related aging-independent drug effects. Therefore, our data largely dissociate longevity itself.